Sino Biopharmaceutical Limited: Carcinoma trials
The registry lists 13 Carcinoma studies with Sino Biopharmaceutical Limited as lead sponsor. 1 are open to participants now and 0 have results posted.
Phase 1 3Phase 2 9Phase 3 4(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A Clinical Trial of TQB2618 Injection Combined With Penpulimab Injection and Chemotherapy Versus Penpulimab Injection Combined With Chemotherapy in First-line Treatment of Relapsed/Metastatic Head and Neck Squamous Cell CarcinomaRecruitingNCT05783921Phase 1/2
- A Clinical Trial to Evaluate Tolerability and Security of TQB2858 Injection in Subjects With Advanced Pancreatic CarcinomaTerminatedNCT05193604Phase 1
- A Clinical Trial to Evaluate TQB2858 Injection Combined With Anlotinib Hydrochloride Capsule in the Treatment of Recurrent or Metastatic Advanced Endometrial CarcinomaStatus unknownNCT05121363Phase 2
- A Study of TQB2450 in Combination With Intensity-modulated Radiotherapy in Patients With Inoperable Locally Recurrent Nasopharyngeal CarcinomaCompletedNCT04895345Phase 2
- A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)Active, not recruitingNCT04344158Phase 3
- Study of TQB2450 in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck（R/M SCCHN）Status unknownNCT03855384Phase 3
- A Study on Safety and Efficacy of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule in Patients With Advanced Biliary Adenocarcinoma/Hepatocellular CarcinomaStatus unknownNCT03825705Phase 1/2
- Gemcitabine and Cisplatin With/Without Anlotinib in Advanced Nasopharyngeal CarcinomaStatus unknownNCT03601975Phase 3
- A Study of Anlotinib in Patients With Hepatocellular CarcinomaStatus unknownNCT02809534Phase 2
- Study of Anlotinib in Patients With Esophageal Squamous Cell Carcinoma (ALTER1102)CompletedNCT02649361Phase 2
- Study of Anlotinib in Patients With Medullary Thyroid Carcinoma(ALTER01031)CompletedNCT02586350Phase 2/3
- Phase II Study of Anlotinib in Patients With Advanced Renal Cell Carcinoma That Have Failed Or Are Intolerant To TKIs TherapyStatus unknownNCT02072044Phase 2
- Phase II Study of Anlotinib Versus Sunitinib in Patients With Advanced Renal Cell Carcinoma（RCC）Status unknownNCT02072031Phase 2